163 related articles for article (PubMed ID: 12529673)
1. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
2. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
4. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
[TBL] [Abstract][Full Text] [Related]
5. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
[TBL] [Abstract][Full Text] [Related]
6. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Kim HP; Frankel AE; Hogge DE
Leuk Res; 2010 Aug; 34(8):1035-42. PubMed ID: 20137810
[TBL] [Abstract][Full Text] [Related]
7. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
Terpstra W; Rozemuller H; Breems DA; Rombouts EJ; Prins A; FitzGerald DJ; Kreitman RJ; Wielenga JJ; Ploemacher RE; Löwenberg B; Hagenbeek A; Martens AC
Blood; 1997 Nov; 90(9):3735-42. PubMed ID: 9345060
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
[TBL] [Abstract][Full Text] [Related]
11. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
12. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy.
Hall PD; Sinha D; Frankel AE
Cancer Immunol Immunother; 2006 Aug; 55(8):928-32. PubMed ID: 16645883
[TBL] [Abstract][Full Text] [Related]
13. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
[TBL] [Abstract][Full Text] [Related]
14. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
15. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
Hall PD; Willingham MC; Kreitman RJ; Frankel AE
Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
[TBL] [Abstract][Full Text] [Related]
16. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
18. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
20. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
